New Delhi, September 13: A vaccine which produces a robust immune response at one go might make swine flu easier to handle, but authorities in India feel any such immunisation needs intensive testing as it may compound any side effects the vaccine might have.
According to Director of Indian Council of Health Research (ICMR), VM Katoch, any vaccine which is introduced in India will have to be tested on the Indian population as any side effects which the vaccine might have will be compounded.
Katoch’s remarks came in the backdrop of reports of a single shot vaccine which is expected to be welcomed by health authorities because it means more people can be protected as quickly as the vaccine becomes available.
A recent study by researchers at CSL Ltd, a global vaccine and plasma protein company with its headquarters in Australia, showed that a single jab fo vaccine might be enough to produce strong antibodies in the body to fight the disease.
The researchers report early results of an ongoing trial that is evaluating a two-dose vaccine in healthy adults between the ages of 18 and 64 at a single site in Australia.
The study was published in the latest issue of the New England Journal of Medicine.
Related Stories
Karnataka swine flu toll rises to 62
Increasing trend of swine flu in India: WHO
The findings suggest that one dose was enough to produce an immunogenic response, with “mild to moderate” side effects.
They also reported that the vaccine appears to have side effects similar to seasonal flu vaccines.
Katoch said if a vaccine is administered in two or three doses like in a normal flu vaccine, then if it has any side effects it would be clear after administering the first dose only.
But in a single shot vaccine which uses a adjoinder, nothing can be done to tackle side effects, he said.
“We have written to all international companies manufacturing the vaccine and asked them to conduct bridging studies in India first. After that we would decide on procuring them,” he said.
The CSL study is based on measures taken 21 days after the first of the two scheduled vaccine shots was given.
“Over 95 per cent of participants receiving the single 15 mcg dose of the vaccine achieved antibody levels that correlate with the prevention of influenza infection,” the CSL announced in a statement.
–Agencies